PE firm continues investments in health care industry by taking a stake in Jaggaer

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/FeelPic)
(Image: Getty/FeelPic)

Related tags: PE, Investment, Health care, Software, Medpace, Bioclinica, acquistion

The strategic sourcing software company Jaggaer has received an investment from international PE firm Cinven.

Cinven will support Jaggaer’s management and operations as it plans to increase assets and capabilities in its spend management suite, The Jaggaer One platform.

According to Jaggaer, the platform uses machine learning and artificial intelligence (AI) capabilities in its network of 4m suppliers to simplify the contracting process for clients taking on existing and potential customers.

Chris Good, partner and co-head of Cinven’s technology, media, and telecom (TMT) team, said in a statement, “As a growing and profitable spend management software business with a very strong track record, and following a number of successful acquisitions, the business is poised for continued significant growth.”

No financial terms of this investment were disclosed.

The UK-based private equity (PE) company has raised a total of €37bn and invested in 135 companies across Europe and North America. The investment in Jaggaer follows investments in Medpace​ in 2014 and Bioclinica​ in 2016.

Related news

Show more

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more